San Diego-based biotech firm Cullgen is poised to enter the public market following its merger with Pulmatrix, a deal marking a significant milestone for both companies. The merger, officially announced this week, aims to combine Cullgen’s cutting-edge genomic technologies with Pulmatrix’s expertise in inhalation therapeutics, positioning the consolidated entity for accelerated growth and expanded investor appeal. This strategic union not only brings Cullgen into the public trading arena but also highlights San Diego’s growing prominence as a hub for innovative life sciences ventures.
Cullgen’s Strategic Move Into the Public Market Through Pulmatrix Merger
In a bold maneuver to expand its footprint in the biopharma sector, Cullgen has announced a merger agreement with…
—-
Author : Charlotte Adams
Publish date : 2025-09-29 04:26:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8
